Historical Perspective on the Use of Retinoids in Cutaneous T-Cell Lymphoma (CTCL)

Clinical Lymphoma

Volumn 1, Issue 1 SUPPL., 2000, Pages

  Burg, Günter ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acitretin; All trans retinoic acid; Cutaneous T cell lymphoma; Etretinate; Isotretinoin

Indexed keywords

RETINOID;

CUTANEOUS T CELL LYMPHOMA; HISTORY; HUMAN; REVIEW; SKIN TUMOR;

HISTORY, 20TH CENTURY; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; RETINOIDS; SKIN NEOPLASMS;

EID: 0002358006     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.s.008     Document Type: Article

References (38)

1. Burg G, Kempf W, Haeffner A, et al. Cutaneous lymphomas. Curr Probl Dermatol 1997; 9:137-204.
2. Burg G, Braun-Falco O. Cutaneous Lymphomas, Pseudolymphomas, and Related Disorders. Berlin: Springer, 1983.
3. Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 1995; 22:11-17.
4. Kligman AM, Fulton JE Jr., Plewig G.Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99:469-476.
5. Bollag W. Retinoids and interferon: a new promising combination? Br J Haematol 1991; 79 (suppl 1):87-91.
6. Peck R, Bollag W. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer 1991; 27:53-57.
7. Sundaresan A, Claypool K, Mehta K, et al. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 1997; 8:1071-1082.
8. Fujimura S, Suzumiya J, Anzai K, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res 1998; 22:611-618.
9. Cheng AL, Chuang SE, Su IJ. Factors associated with the therapeutic efficacy of retinoic acids on malignant lymphomas. J Formos Med Assoc 1997; 96:525-534.
10. Meunier L, Bohjanen K, Voorhees JJ, et al. Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD1 1c, a beta 2 integrin critically involved in T-cell activation. J Invest Dermatol 1994; 103:775-779.
11. Rook AH, Kubin M. Fox FE, et al. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann N Y Acad Sci 1996; 795:310-318.
12. Vowels BR, Cassin M, Vonderheid EC, et al. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99:90-94.
13. Dummer R, Kohl O, Gillessen J, et al. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch Dermatol 1993; 129:433-436.
14. Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53:358-388.
15. Marks R. Retinoids in Cutaneous Malignancy. Boston: Blackwell Scientific Publications, 1991.
16. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol 1992; 3:513-526.
17. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-572.
18. Sacchi S, Russo D, Avvisati G, et al. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Haematologica 1997; 82:106-121.
19. Foss FM, Kuzel TM. Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1127-1137.
20. Jorg B, Kerl H, Thiers BH, et al. Therapeutic approaches in cutaneous lymphoma. Dermatol Clin 1994; 12:433-441.
21. Kessler JF, Meyskens FL Jr., Levine N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet 1983; 1:1345-1347.
22. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987; 67:232-236.
23. Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991; 24:247-252.
24. White SD, Rosychuk RA, Scott KV, et al. Use of isotretinoin and etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs. J Am Vet Med Assoc 1993; 202:387-391.
25. Claudy AL, Rouchouse B, Boucheron S, et al. Treatment of cutaneous lymphoma with etretinate. Br J Dermatol 1983; 109:49-56.
26. Thestrup-Pedersen K, Hammer R, Kaltoft K, et al. Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. Br J Dermatol 1988; 118:811-818.
27. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92:3578-3581.
28. Bauch B, Narraud-Klenowssek M, Burg G, et al. Eindrucksvolle remission einer mycosis fungoides im tumorstadium unter low-dose interferon und acitretin nach erfolgloser Chemotherapie. Z Hautkr 1995; 70:200-203.
29. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15:790-795.
30. Harms M. Systemisches Isotretinoin. Roche Editiones, 1994.
31. Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987; 123:201-204.
32. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med 1987; 147:529-531.
33. Claudy AL, Delomier Y, Hermier C. Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (Ro 10-9359). Arch Dermatol Res 1982; 273:37-42.
34. Tousignant J, Raymond GP, Light MJ. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298. J Am Acad Dermatol 1987; 16:167-171.
35. Wargon O, Downie D. A case of mycosis fungoides treated with etretinate. Australas J Dermatol 1984; 25:77-79.
36. Dreno B. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells 1993; 11:269-275.
37. Altomare GF, Capella GL, Pigatto PD, et al. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 1993; 32:138-141.
38. Torii H, Kaneko T, Matsuyama T, et al. Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides. J Dermatol 1994; 21:767-770.